WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Economy in transition GNI / capita (US$): 8'0201 Infant (under 12 months) mortality rate: 442
GDP / capita (US$): 15'4741 Child (under 5 years) mortality rate: 512

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 5'374  5'307  5'240  5'173  5'107  4'501  3'668  2'861 
Births 112  112  112  111  111  107  130  99 
Surviving infants 107  107  107  106  105  101  120  90 
Pop. less than 5 years 528  522  513  503  500  490  579  437 
Pop. less than 15 years 1'517  1'507  1'493  1'477  1'470  1'634  1'484  1'182 
Female 15-49 years 1'507  1'495  1'485  1'476  1'463  1'193  875  661 

Number of reported cases

(Click for retrospective incidence data for Turkmenistan)
Diphtheria
ChartChart
  30 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  113  2'806 
Mumps
ChartChart
  14  27  13  31  1'124 
Pertussis
ChartChart
  11  260 
Polio*
ChartChart
 
Rubella
ChartChart
  129 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Turkmenistan)
Vaccine year result method % card seen                                                
BCG 1994  92  MICS     99  99  99  99  98  99 
DTP1          99  99  99  98  98  97 
DTP3 1994  82  MICS     99  98  98  97  97  97 
DTP4          97  97 
IPV1         
HepB_BD          99*  99  99*  99*  99* 
HepB3          99  97  98  98  97 
Hib3          99  97  97  97  71 
JapEnc         
MCV1          99*  99  99  99  99  97 
MCV2          99*  99  99  99  99  92 
PCV1         
PCV3         
Pol3 1994  86  MICS     99  98  98  98  97  98 
Rota1         
RotaC         
Rubella1          99*  99  99  99  99 
TT2plus          99 
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Turkmenistan)
BCG
ChartChart
  99  99  98  99  98  99 
DTP1
ChartChart
  99  99  99  98  98  97 
DTP3
ChartChart
  99  98  98  97  97  97 
HepB3
ChartChart
  99  97  98  98  97 
HepB_BD
ChartChart
  99  99  99  99  99 
Hib3
ChartChart
  99  97  97  97  71 
IPV1
ChartChart
 
MCV1
ChartChart
  99  99  99  99  99  96 
MCV2
ChartChart
  99  99  99  99  99  92 
PCV3
ChartChart
 
Pol3
ChartChart
  99  98  98  98  97  98 
RCV1
ChartChart
  99  99  99  99  99 
RotaC
ChartChart
 

Number of districts in the country 67  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 3 days; 14 years; Yes
DT 6 years; Yes
DTwP 18 months; Yes
DTwPHibHepB 2, 3, 4 months; Yes
HPV Yes From June 2016
HepB_Pediatric birth; Yes
IPV Yes From June 2016
Influenza_Adult Yes health care workers, pregnant women, Haj and travelers, and other risk groups
MMR 12-15 months; 6 years; Yes
OPV birth; 2, 3, 4, 18 months; Yes
Td 15, 25 years; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2003-2020  2003-2020  2003-2020  2003-2020  2003-2020  2003-2020  Yes 
Nº of districts with microplans that include activities to raise immunization coverage number 67  67  67  67  67    61 

System performance

Total Nº districts in country number 67  67  67  67  67  64  64 
Nº districts with DTP3 coverage >=80% number 67  67  67  67  67  64  64 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 67  67  67  67  67  64  64 
% of districts with MCV1 coverage >=95% From 0 to 100% 100  100  100  100  100  100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  NA    No  NA     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.